Conference Call Scheduled for Financial Results
Abeona Therapeutics Inc. (NASDAQ: ABEO) has exciting plans to host a conference call aimed at discussing the outcomes of its third-quarter financial results. This conference, set for a Wednesday session at 8:30 a.m. ET, marks a significant opportunity for investors and analysts to delve deeper into the company’s performance and strategic direction.
Accessing the Conference Call
Those wishing to attend can join the call via phone or a webcast. For phone access, individuals can dial either 877-545-0523 for U.S. participants or 973-528-0016 for international calls, ensuring to provide Entry Code: 922481 shortly before the call begins. The company will also facilitate a live listen-only webcast, which will later be available for replay on their Investors & Media section of the Abeona website for up to 30 days following the event.
Participation in the Stifel Healthcare Conference
The Abeona team will also feature at the Stifel 2025 Healthcare Conference, presenting insights during a fireside chat on Thursday at 1:20 p.m. Eastern Time. Investors eager to listen can find a live webcast on the Abeona website under 'Events'. Furthermore, this chat will also be archived for future viewing, making it accessible even if you miss the live discussion.
About Abeona’s Innovative Therapies
Abeona Therapeutics specializes in pioneering biopharmaceutical solutions, focusing predominantly on cell and gene therapies designed to combat severe illnesses. One of their flagship products is ZEVASKYN, recognized as the first and only autologous cell-based gene therapy aimed at treating wounds in patients afflicted by recessive dystrophic epidermolysis bullosa (RDEB), which greatly demonstrates their commitment to addressing rare diseases.
Strong Manufacturing Capabilities
Abeona’s cutting-edge facility located in Cleveland, Ohio, is fully equipped for the commercial production of ZEVASKYN. The company continues to invest significantly in its development portfolio which utilizes adeno-associated virus (AAV)-based gene therapies targeting ophthalmic conditions that currently have an unmet medical need. The unique capabilities of Abeona's next-generation AAV capsids are being explored in various critical applications.
Looking Ahead with Abeona Therapeutics
As the company navigates future challenges and opportunities, their commitment to innovation remains steadfast. Investors are encouraged to stay informed and engaged as Abeona Therapeutics reveals insightful updates during upcoming calls and conferences.
Frequently Asked Questions
What is the date of the upcoming conference call?
The conference call is scheduled for Wednesday at 8:30 a.m. ET.
How can I access the conference call?
You can access the call via phone at specified numbers or through a webcast available on the Abeona website.
What event will Abeona participate in after the conference call?
Abeona will participate in the Stifel 2025 Healthcare Conference on November 13, 2025.
What is ZEVASKYN?
ZEVASKYN is the first autologous cell-based gene therapy aimed at treating wounds in RDEB patients.
Where is Abeona Therapeutics located?
Abeona Therapeutics is based in Cleveland, Ohio, where they also operate their manufacturing facility for ZEVASKYN.
